/DISCLAIMER · RESEARCH_COMPOUND

This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.

/ARA_290_CIBINETIDE
Peptide

ARA-290

Non-erythropoietic EPO-Derived Peptide

/HALF_LIFE
Short (~20 minutes after SC; minutes after IV), with pharmacodynamic effects outlasting plasma exposure
/DELIVERY
Subcutaneous injection (e.g., once daily in 28-day study designs); IV used in early PK work.

/WHAT_IT_IS

ARA-290 (cibinetide) is an 11–amino acid peptide engineered from erythropoietin’s helix-B that selectively activates the EPOR–CD131 ‘innate repair receptor’ to promote tissue protection, anti-inflammatory signaling, and small-fiber nerve repair without stimulating erythropoiesis.

/USAGE

Studied in small fiber neuropathy (e.g., sarcoidosis-associated and type 2 diabetes), ocular/ischemic injury models, and inflammatory conditions to evaluate symptom relief, nerve fiber regeneration, and improved metabolic/quality-of-life outcomes.

/MECHANISM_OF_ACTION

Binds the EPOR–CD131 heteroreceptor (innate repair receptor), triggering JAK2/STAT and PI3K/Akt pathways while suppressing NF-κB–mediated inflammation; restores tissue homeostasis and supports small-fiber nerve regrowth.

Reported Benefits

  • +Reduces neuropathic pain and autonomic symptoms in SFN studies
  • +Improves quality-of-life measures
  • +Increases corneal small-fiber nerve density in clinical imaging
  • +Anti-inflammatory, cytoprotective effects without erythropoiesis
  • +Metabolic improvements noted in type 2 diabetes cohorts

Reported Side Effects

  • Generally well tolerated in trials
  • Mild injection-site reactions
  • No meaningful changes in hematocrit/hemoglobin (non-erythropoietic)

/STACKED_WITH

Glycemic-control agents in T2D research (comparator/adjunct design)Standard neuropathic-care paradigms (e.g., physical therapy) for functional endpointsOmega-3s or antioxidant protocols in inflammation models (research context)

/RESEARCH_NOTES

Selective IRR activation aims to reprogram inflammatory microenvironments toward repair. Clinical studies in sarcoidosis-associated and diabetic SFN report symptom improvement and corneal nerve fiber regrowth, with a favorable safety profile despite a very short plasma half-life.

/REFERENCE

https://pubmed.ncbi.nlm.nih.gov/25387363/
/TRACK_THIS

Browse all 89 in the app.

MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.

Last reviewed: 2026-06-04 · Reference only. Not medical advice. Consult a qualified physician.